Liver fat accumulation is associated with circulating PCSK9-Reference-Cited by-同舟云学术

Liver fat accumulation is associated with circulating PCSK9

Published:2016-05-25 Issue:5 Volume:48 Page:384-391
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Ruscica Massimiliano¹,Ferri Nicola²,Macchi Chiara¹,Meroni Marica³,Lanti Claudia⁴,Ricci Chiara¹,Maggioni Marco⁵,Fracanzani Anna Ludovica³⁴,Badiali Sara⁶,Fargion Silvia³⁴,Magni Paolo¹,Valenti Luca³⁴,Dongiovanni Paola⁴

Affiliation:

1. Department of Pharmacological and Biomolecular Sciences, Università Degli Studi Di Milano, Milano, Italy;

2. Department of Pharmaceutical and Pharmacological Sciences, Università di Padova, Padova, Italy;

3. Department of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milano, Italy;

4. Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;

5. Department of Pathology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;

6. Department of Surgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2016.1188328

Reference32 articles.

1. Association of nonalcoholic fatty liver disease with insulin resistance

2. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects

3. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

4. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis

5. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition;European Journal of Clinical Investigation;2024-06-26

2. A promising therapy for fatty liver disease: PCSK9 inhibitors;Phytomedicine;2024-06

3. Identification of key markers for the stages of nonalcoholic fatty liver disease: An integrated bioinformatics analysis and experimental validation;Digestive and Liver Disease;2024-06

4. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin;Frontiers in Endocrinology;2024-05-23

5. Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome;European Cardiology Review;2024-05-09